利拉鲁肽对型糖尿病患者血浆丝氨酸蛋白酶抑制剂水平的影响的论文.docVIP

利拉鲁肽对2型糖尿病患者血浆丝氨酸蛋白酶抑制剂水平的影响的论文 利拉鲁肽对2型糖尿病患者血浆丝氨酸蛋白酶抑制剂水平的影响 【关键词】 丝氨酸蛋白酶抑制剂;2型糖尿病;利拉鲁肽 【摘要】 目的 探讨胰高糖素样肽1(glp1)类似物利拉鲁肽(liraglutide)对2型糖尿病(t2dm)患者血浆丝氨酸蛋白酶抑制剂(vaspin)水平的影响。方法 采用酶联免疫法测定t2dm患者及正常人vaspin水平，分析血浆vaspin水平与体重指数(bmi)、腰臀比(whr)、胰岛素抵抗指数(homair)、胰岛素分泌指数(homais)、游离脂肪酸(ffa)等的关系，观察利拉鲁肽治疗前后t2dm患者血浆vaspin水平变化。结果 t2dm患者血浆vaspin水平显著高于正常人(plt;0.05)。血浆vaspin水平与空腹血糖(fpg)及糖化血红蛋白(hba1c)呈明显正相关(r=0.35,plt;0.01和r=0.25,plt;0.05)，而与dbp呈明显负相关(r=-0.25，plt;0.05)，fpg、whr分别是影响血浆vaspin水平的独立相关因素。t2dm患者经利拉鲁肽治疗后，体重、bmi、whr、fpg、餐后2小时血糖(2 h pg)、hba1c均显著降低(plt;0.01)，而homais则显著增高(plt;0.01)，空腹血浆vaspin也显著增高(plt;0.05)。结论 利拉鲁肽能有效改善t2dm患者糖脂代谢和胰岛素敏感性，增强胰岛β细胞功能，同时升高血浆vaspin水平。WwW.11665.Com 【关键词】 丝氨酸蛋白酶抑制剂;2型糖尿病;利拉鲁肽 　【abstract】 objective to investigate the effects of longacting human glucagonlike peptide1(glp1) analog liraglutide on plasma vaspin level in patients with type 2 diabetes mellitus (t2dm). methods plasma vaspin level was measured by elisa in patients with t2dm and normal controls (ngt).the relationship between plasma vaspin levels and bmi, whr, homair, homais, ffa were also analyzed. after liraglutide treatment, plasma vaspin levels was observed in patients with t2dm.results t2dm group had significantly higher plasma vaspin levels than that of ngt group 〔(0.73±0.32) vs.(0.54±0.22) μg/l, plt;0.05〕. plasma vaspin level was correlated positively with fpg,hba1c (r=0.35, plt;0.01 and r=0.25, plt;0.05) and negatively with dbp(r=-0.25，plt;0.05). fpg and whr were independently associated with plasma vaspin level. after liraglutide treatment, body weight, whr, bmi, 2 h pg, fpg and hba1c were significantly decreased (all plt;0.01), and homais level was significantly increased(plt;0.01)in t2dm patients. interestingly, fasting plasma vaspin level was also significantly increased on posttreatment with liraglutide 〔(0.73±0.32) vs. (0.92±0.38) μg/l, plt;0.05〕.conclusions liraglutide can remarkably improve glucose and lipid metabolism, insulin resistance, as well as pancreatic βcell funct